Cordicity
Request a demo



.

Patient-specific cardiac blood flow insights from standard CT imaging. CorASCT maps blood stagnation automatically — turning routine scans into a new clinical signal for stroke risk.

Request a demo→Join the team
Almi Invest
LiU InvestEast Sweden Capital
LEAD
Almi Invest
LiU InvestEast Sweden Capital
LEAD
Why it matters

Cardiac blood flow — a silent risk marker.

Deviated flow in the left atrium drives thrombus formation — the dominant mechanism behind ischemic stroke. Today's risk scores miss the patient. The signal lives in the scan.

0M+
Atrial fibrillation patients globally
5× folded stroke risk
0M+
Annual strokes worldwide
20% caused by AF
0M+
Living with post-stroke sequelae
Long-term disability burden
0B€+
Global economic burden
Healthcare + lost productivity
The solution

Introducing CorASCT.
More than improved imaging.

Automated blood stagnation mapping from a standard CT — a new quantitative marker for clinicians, designed for cloud-native distribution through existing PACS platforms.

01
Patient-specific

Computes hemodynamics per case — no population averages, no proxies.

02
Standard CT input

Works with any CT vendor and the systems that already exist in hospitals today.

03
Cloud-native

Delivered as an automated application integrated into PACS and AI marketplaces — without any manual intervention.

How it works

AI powered segmentation.

Not a render. The model identifies target cardiac structures from a routine CT, which are tracked over time and feed advanced hemodynamic computations.

Scene 01 · Whole heart
Scene 01 · Whole heart
01 / 04

This is the actual segmentation.

Not a render. The model identifies seven cardiac structures from a routine CT — the same data that feeds the hemodynamic computation in step 03.

Scene 02 · Left side
02 / 04

Where stasis matters.

The left atrium and left ventricle are the chambers where slow, recirculating blood drives thromboembolic risk. Cordicity quantifies stagnation here.

Scene 03 · Right side
03 / 04

Right-side anatomy, isolated.

Right atrium and right ventricle are segmented with the same model — enabling full four-chamber flow analysis when needed.

Scene 04 · Outflow tracts
04 / 04

Inflow and outflow, quantified.

Aorta and pulmonary artery boundaries define the flux surfaces. PV inflow and MV outflow are computed directly from these — step 03 takes over from here.

Book a demo
Use cases

Built for clinical impact
and scalable distribution.

Stroke care
Strengthen stroke origin assessments

Improve stroke care with patient-specific stagnation data when a cardioembolic origin is suspected — identify the silent high-risk patient.

Ablation therapy
Transforming atrial fibrillation ablation

Move beyond ablation for symptomatic AF patients and optimise resources — prioritise ablation for stroke risk reduction.

Anticoagulant decision
Decision support for treatment

Informed anticoagulation strategy and decisions with a new precision marker that complements existing clinical risk scores.

Market

A €4.5B opportunity hiding in plain sight.

CorASCT addresses converging clinical workflows across ablation therapy, stroke care and anticoagulation decisions — defining a meaningful addressable market for an integrated, CT-native solution.

Ablation priority
€1.0B
Stroke care
€1.5B
NOAC decision
€2.0B
TAM
€0.0B
Total addressable
SAM
€0.0B
Serviceable
SOM
€0M
5-year obtainable
Traction

Momentum across capital, clinic and channel.

Backed by leading Nordic investors and progressing toward integrated distribution through the imaging platforms clinicians already use — with an interdisciplinary team, strong IP and a maturing clinical evidence base.

IP
Strong patent applications filed
Market
Collaboration with leading distributors and hospitals
TRL
5
Research
Several high-impact publications
Team
Interdisciplinary expert founders
Investments
€700k+
Roadmap
2020–2023
Research
Strong research funding attracted
2023
Foundation
Key entrepreneurs in incubator programs
2024
Soft funding
Strong grant attraction
2025
Pre-seed round
€50k — LiU Invest
2026
Seed round
€650k — Almi Invest, East Sweden Capital et al.
2027
Pre-Series A
Clinical studies & MDR 2A path
2028
Clinical launch
CorASCT · MDR 2A clearance
2029
Scaling
NAM expansion · FDA clearance
Team

Clinicians, computational scientists and entrepreneurs.

Linus Ohlsson, MD, PhD
Linus Ohlsson, MD, PhD
Co-founder · CEO
Jonas Lantz, PhD
Jonas Lantz, PhD
Co-founder · CTO
Tino Ebbers, Prof.
Tino Ebbers, Prof.
Co-founder · CSO
Erik Birgersson, MSc
Erik Birgersson, MSc
Software Engineer
Bild kommer
Felix Wennerstein
Junior market analyst
Board
  • Gunilla Åberg — Acting chairman
  • Matts Karlsson, Prof. — Co-founder
  • Anders Persson, Prof. — Co-founder
  • Åsa Wallin — Almi Invest
  • Björn Persson — East Sweden Capital
We are hiring
Join the people rewriting cardiac risk.

We are recruiting a senior software engineer to help scale CorASCT — join a small, interdisciplinary team building the next quantitative marker in stroke care.

Cordicity

More than improved imaging.

Talk to the team building the next quantitative marker in stroke care — whether you are a clinician, a partner, an investor or a future colleague.

Request a demo→Partner with us